Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EP652
- Development stage
- Unknown
- Lead developer
- EPICS Therapeutics
- Modality
- Small Molecules
- Administration
- Intraperitoneal
01
Overview
EP652 is a small-molecule inhibitor of methyltransferase-like 3 (METTL3), developed by Epic Therapeutics. It is primarily characterized as a proof-of-concept research tool compound rather than an active clinical candidate. The compound was notably used in a collaborative in silico modeling methodology study with Cresset, which was published in the Journal of Medicinal Chemistry. METTL3 is a key enzyme in the m6A RNA methylation process, a critical epigenetic mechanism linked to various cancers and inflammatory diseases. EP652 serves to validate computational drug discovery workflows targeting this complex.
- Other names
- EP652EP-652EP 652
02
Targets
METTL3 (Methyltransferase-like protein 3)
Beyond the preview
Go deeper on EP652.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP652.